Pharmacokinetic study of acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters

Vijayshree Yadav, Gail H. Marracci, Myrna Y. Munar, Ganesh Cherala, Lauren E. Stuber, Lilia Alvarez, Lynne Shinto, Dennis R. Koop, Dennis N. Bourdette

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C max in μg/ml) and area under the curve0-infinity (AUC0-infinity in ng*min/ml). We found mean C max and AUC0-infinity in patients with multiple sclerosis as follows: group A (N = 7) 3.8 ± 2.6 and 443.1 ± 283.9; group B (N = 8) 9.9 ± 4.5 and 745.2 ± 308.7 and group C (N = 8) 10.3 ± 3.8 and 848.8 ± 360.5, respectively. Mean Cmax and AUC0-infinity in the mice were: 100 mg/kg lipoic acid: 30.9 ± 2.9 and 998 ± 245; 50 mg/kg lipoic acid: 7.6 ± 1.4 and 223 ± 20; 20 mg/kg lipoic acid: 2.7 ± 0.7 and 119 ± 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum Cmax and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)387-397
Number of pages11
JournalMultiple Sclerosis
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2010

Keywords

  • Anti-oxidants
  • Dietary supplements
  • Experimental autoimmune encephalomyelitis
  • Lipoic acid
  • Multiple sclerosis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pharmacokinetic study of acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters'. Together they form a unique fingerprint.

  • Cite this